Alkermes (ALKS) Projected to Post Earnings on Wednesday

Alkermes (NASDAQ:ALKS) is projected to release its earnings data before the market opens on Wednesday, February 12th. Analysts expect Alkermes to post earnings of $0.81 per share and revenue of $379.74 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Alkermes Trading Down 1.1 %

Shares of ALKS opened at $31.23 on Tuesday. Alkermes has a 12-month low of $22.90 and a 12-month high of $32.88. The firm has a market capitalization of $5.05 billion, a P/E ratio of 16.02, a P/E/G ratio of 1.83 and a beta of 0.49. The firm has a 50-day moving average price of $30.08 and a 200 day moving average price of $28.60. The company has a current ratio of 3.45, a quick ratio of 3.03 and a debt-to-equity ratio of 0.22.

Insider Activity at Alkermes

In related news, EVP Craig C. Hopkinson sold 100,918 shares of the business’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $32.05, for a total transaction of $3,234,421.90. Following the completion of the transaction, the executive vice president now directly owns 44,290 shares of the company’s stock, valued at $1,419,494.50. The trade was a 69.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Cato T. Laurencin sold 2,691 shares of the company’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $31.85, for a total value of $85,708.35. Following the sale, the director now owns 23,013 shares in the company, valued at approximately $732,964.05. This trade represents a 10.47 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 179,189 shares of company stock worth $5,723,518. Corporate insiders own 4.89% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on ALKS shares. HC Wainwright reissued a “neutral” rating and issued a $37.00 price target on shares of Alkermes in a research note on Friday, October 25th. JPMorgan Chase & Co. lowered their price objective on Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Cantor Fitzgerald reduced their target price on Alkermes from $48.00 to $43.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. The Goldman Sachs Group decreased their price target on Alkermes from $32.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. Finally, Mizuho boosted their price objective on shares of Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, Alkermes has an average rating of “Moderate Buy” and a consensus target price of $36.00.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.